Alliance Pharma to Delist After $427 Million Takeover by DBAY Advisors

The deal marks another departure from the London Stock Exchange's AIM market, as private equity firms target undervalued UK-listed companies.

Alliance Pharma's board has unanimously recommended a £349.7 million ($427 million) takeover offer from DBAY Advisors and Edmond de Rothschild’s ERES IV fund.
Shareholders are set to receive 62.5 pence per share, a 41% premium over the company's most recent closing price.
The acquisition follows years of financial challenges for the Chippenham-based company, including debt accumulation, market struggles, and leadership changes.
DBAY Advisors, which already holds a 28% stake in Alliance, stated that the company requires time away from public markets to implement its strategic initiatives and accelerate growth.
The deal continues a trend of private equity takeovers shrinking the London Stock Exchange, particularly among AIM-listed companies facing liquidity and valuation pressures.